Set as preferred source
Insights from Innovation in Women’s Health.
Women’s health is becoming harder to treat as a standalone healthcare category.
That is the more important conclusion from Silicon Valley Bank’s Innovation in Women’s Health report. The market is expanding beyond fertility, contraception, menopause and maternal care into cardiovascular disease, autoimmune conditions, mental health, neurology and other areas where biological differences materially affect diagnosis and treatment.
The numbers make the shift visible. Since 2020, SVB identifies about 210 companies and $6.4 billion in venture investment addressing conditions unique to women, another 120 companies and $4.4 billion focused on conditions that disproportionately affect women, and 55 companies with $745 million targeting diseases that affect women differently.
This is not simply a larger definition of the same market. It changes where value can accumulate. Women’s health is increasingly becoming an entry point into precision medicine, longitudinal care and data-driven healthcare rather than a collection of isolated point solutions.
And that shift is happening just as capital becomes more selective.
The funding decline tells the wrong story if read in isolation
Women’s health venture investment peaked at roughly $3 billion in 2024 before falling in 2025. At first glance, that looks like weakening momentum.
The underlying picture is more nuanced.
Much of healthcare’s recent investment growth has been pulled toward large AI rounds in drug discovery, revenue-cycle management and provider operations. Those businesses largely sit outside SVB’s definition of women’s health, which remains more concentrated in therapeutics, devices and alternative care models.
The 2025 decline partly reflects where healthcare AI investment was concentrated, rather than a straightforward loss of investor confidence in women’s health.
SVB’s early 2026 data also pointed toward a rebound in both funding and deal activity. That outlook was based on projections made in May, not completed full-year results.
That distinction matters because AI-focused companies inside women’s health are receiving a very different treatment. AI represented about 20% of women’s health deals in 2025, while median pre-money valuations for AI-focused companies reached $35 million, compared with $12.3 million across women’s health companies overall.
Capital has not disappeared. But women’s health still represents a relatively small share of healthcare venture investment: just 5.7% of deals and 3.1% of invested dollars in 2025.
Investors are becoming more specific about the operating models they will back.
That selectivity becomes even clearer further down the financing ladder. Seed-to-Series A graduation fell from 27% for the 2020 cohort to 13% for the 2023 cohort. Series A-to-Series B progression dropped from 40% for companies entering Series A in 2019 to 19% for the 2023 cohort.
The market can still finance formation. Scaling is becoming the harder part.
That puts more weight on clinical evidence, regulatory progress and a credible path to commercialization. Devices and biopharma have already moved above their 2021 investment baselines, while healthtech remains below its earlier level and diagnostics/tools have recovered only partially. The difference is increasingly one of proof.
Consolidation offers another route. Acquisitions continued in 2025, alongside a sharp increase in IPO activity. SVB points to strategic buyers acquiring smaller healthcare businesses for their capabilities, patient relationships and contracts. For some companies, becoming part of a larger care platform may prove more realistic than building one independently.
The real infrastructure bottleneck is access
The technology story is easier to see than the infrastructure problem underneath it.
About 35% of US counties have no birthing facility or obstetric clinician. Primary-care shortages are not confined to remote markets either. California has roughly 14 million women living in counties classified as severe primary-care shortage areas, followed by Texas at 8.8 million and Florida at 7.7 million.
This changes the role of digital care.
Telehealth is often discussed as another healthcare channel. In this market, it increasingly looks like a capacity layer for a system that cannot build physical supply fast enough.
Women account for 59% of rural telemedicine users in the report’s dataset, and those users carry significantly greater medical complexity: heart failure prevalence is 2.7 times higher than among rural non-users, while depression is 2.5 times higher.
More importantly, digital access can affect expensive downstream outcomes. One virtual maternity-care program cited by SVB was associated with a 24% reduction in preterm births and a 26% reduction in average NICU stay length.
That is a different economic proposition from convenience-based telemedicine. The value moves toward keeping higher-risk patients connected, identifying deterioration earlier and reserving scarce physical capacity for the cases that need it most.
This helps explain why longitudinal models such as Midi Health, Maven and Pomelo Care matter beyond their individual service offerings. The important asset is increasingly the ongoing relationship through which different specialties, interventions and datasets can be connected over time.
AI is winning capital where it changes clinical economics
Women’s health AI is also developing differently from the broader healthcare AI market.
The strongest activity is not centered on general-purpose assistants. It is concentrated in diagnostic analytics, provider operations, non-invasive monitoring, testing and oncology.
In diagnostics and tools, AI-enabled businesses represent approximately 65% of companies but 73% of venture deals. In healthtech, about 30% of companies are AI-enabled, yet they capture 46% of deals. In biopharma, the divergence is even wider: roughly 27% of companies account for 57% of deals.
The pattern is fairly clear. Capital is favoring systems that can turn imaging, genomic, laboratory, biometric or clinical information into repeatable decisions without increasing headcount at the same rate as revenue.
But the valuation premium comes with a constraint that consumer technology rarely faces at the same intensity: trust.
A 2023 Pew Research Center survey cited by SVB found that 66% of US women would trust a healthcare provider less if that provider relied on AI. Women were also more skeptical than men about AI improving healthcare quality.
That creates an unusual market tension. The same technology that can improve operating leverage can weaken adoption if patients do not trust how it influences care.
And trust is not just a communication problem. Women have historically been underrepresented in clinical research, creating gaps in the data used to develop medical AI. Systems trained on incomplete or biased data risk reproducing the same diagnostic blind spots they are supposed to correct. Some companies are responding by expanding real-world datasets and developing more targeted algorithms.
Regulation becomes part of the product architecture here. The FDA’s approach to Software as a Medical Device distinguishes between tools that display or communicate health information and those that interpret medical signals, estimate disease risks or guide clinical decisions.
The dividing line is not simply whether a product uses AI. Its intended medical purpose, the decisions its outputs support and whether clinicians can independently assess those outputs all matter.
Consumer platforms are starting to blur the market boundary
There is another competitive shift sitting just outside the report’s formal market definition.
Oura is not counted among SVB’s core women’s health unicorns, yet the report notes that more than 60% of its user base is female and that the platform already includes multiple women’s health capabilities.
That matters because wearable platforms enter healthcare from the opposite direction.
Traditional care businesses usually acquire patients when a problem appears. A wearable can establish a daily relationship years earlier, accumulating sleep, activity, temperature and other longitudinal signals before the user ever enters a clinical pathway.
The competitive advantage is therefore not simply hardware.
It is data continuity.
As fertility, cardiovascular risk, metabolic health, menopause and other categories become more personalized, platforms that already have recurring user relationships can become increasingly valuable distribution and data layers for clinical services built around them.
The boundary between consumer wellness and clinical infrastructure is becoming less stable.
The science itself remains a capital constraint
Not every underfunded area is simply waiting for more money.
SVB’s analysis finds an average of about $1,301 in venture investment per disability-adjusted life year across the diseases it examines. Chronic kidney disease, mental health and women’s oncology average only $474 per DALY.
Women-specific research can be thinner still. The report identifies 21 active trials in endometriosis and just 10 in menopause, compared with 62 in autoimmune disease.
Pregnancy exposes the deeper problem.
Historically, some therapies were tested because existing drugs had acceptable safety profiles in pregnancy, not because there was a strong biological theory explaining why they should work. When those repurposing efforts failed, the failures themselves made subsequent funding more difficult.
This creates a feedback loop: thin research produces weaker therapeutic hypotheses; weak hypotheses produce failed trials; failed trials reinforce capital caution.
The implication is important. Market size alone does not remove scientific risk. In under-researched categories, mechanism quality and evidence generation become part of the financing infrastructure.
Regional scale will not be uniform
There is also a geographic limitation worth keeping visible.
SVB’s venture analysis primarily covers the US and Europe, while its most detailed infrastructure data — maternity deserts, physician shortages and rural telehealth utilization — is US-specific. The report does not provide comparable Asia-Pacific datasets.
That makes a simple global-growth narrative difficult to support.
The underlying technologies may travel globally, but the economics of care delivery depend heavily on reimbursement systems, clinical capacity, regulation and who controls the patient relationship. The source provides strong evidence for a US access problem and a transatlantic capital market; it does not establish that every region will follow the same commercialization path.
Risk is shifting from demand to execution
The sector no longer looks constrained mainly by whether women’s health represents a large enough market. The harder risks are now further inside the operating model:
- Capital progression: funding exists, but fewer companies are advancing cleanly from one institutional round to the next.
- Clinical validation: biological rationale and measurable outcomes increasingly separate scalable assets from category enthusiasm.
- Access capacity: digital delivery can extend scarce healthcare infrastructure but cannot remove the need for physical intervention.
- AI trust and regulation: stronger algorithms do not automatically translate into adoption, particularly when systems move closer to clinical decision-making.
- Platform convergence: wearable and consumer-health businesses can enter the market with existing users, longitudinal data and distribution already in place.
Taken together, these constraints point to a broader transition.
Women’s health is moving from a collection of underserved niches toward a test case for what modern healthcare increasingly looks like: longitudinal rather than episodic, data-rich rather than condition-isolated, digitally extended but clinically constrained, and financed according to evidence rather than narrative.
The largest shift may therefore be outside the category itself.
Women’s health is becoming one of the places where healthcare learns how to combine precision medicine, AI, virtual delivery and continuous patient data into a single operating model. The companies that create value in that environment will not be defined only by the conditions they treat. They will be defined by how much of the care relationship, evidence base and data layer they can connect.
